Lexeo Therapeutics Raises $135 Million

By Hao Liu • Sunday, October 19 10:22 • Permanent Link

Lexeo Therapeutics, Inc. has announced the pricing of its underwritten public offering and concurrent private placement, which is expected to generate gross proceeds of approximately $135 million. The company offered 15,625,015 shares of its common stock in the public offering at an offering price of $8.00 per share. Additionally, Lexeo agreed to sell pre-funded warrants to purchase 1,250,000 shares of common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant in a private placement.

The public offering and concurrent private placement are expected to close on or about October 20, 2025. Leerink Partners, Cantor, Stifel, and Oppenheimer & Co. are acting as joint book-running managers for the public offering, while Baird is acting as the lead manager for the public offering. Leerink Partners served as the sole placement agent in connection with the concurrent private placement.

The public offering is being made pursuant to a registration statement on Form S-3, including a base prospectus, previously filed with and declared effective by the U.S. Securities and Exchange Commission. Lexeo has also filed a preliminary prospectus supplement and accompanying prospectus relating to the public offering, with a final prospectus supplement and accompanying prospectus expected to be filed with the SEC.

The pre-funded warrants to purchase shares of common stock to be sold in the concurrent private placement have not been registered under the Securities Act or under any state securities laws.

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that target the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. Following these announcements, the company's shares moved -0.68%, and are now trading at a price of $8.77. For the full picture, make sure to review Lexeo Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.